Koyfin Home > Directory > Health Care > Amneal Pharmaceuticals Inc > Long-Term Debt

Amneal Pharmaceuticals Inc Long-Term Debt Chart (AMRX)

Amneal Pharmaceuticals Inc annual/quarterly Long-Term Debt from 2016 to 2018.
  • Amneal Pharmaceuticals Inc Long-Term Debt for the quarter ending December 12, 2018 was $2,670m a 47.85% increase of 1,277m year over year
  • Amneal Pharmaceuticals Inc Long-Term Debt for the last 12 months ending December 12, 2018 was $2,670m a 47.85% increase of 1,277m year over year
  • Amneal Pharmaceuticals Inc Annual Long-Term Debt for 2018 was $2,670m a 47.74% increase of 1,274m from 2017
  • Amneal Pharmaceuticals Inc Annual Long-Term Debt for 2017 was $1,395m a 16.89% increase of 236m from 2016
  • Amneal Pharmaceuticals Inc Annual Long-Term Debt for 2016 was $1,160m a 17.93% increase of 208m from 2015
Other Cash Flow Metrics:
  • Amneal Pharmaceuticals Inc Cash Flow from Operations for the quarter ending December 12, 2018 was $260m a 89.59% increase of 233m year over year
  • Amneal Pharmaceuticals Inc Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $215m a 94.17% increase of 202m year over year
  • Amneal Pharmaceuticals Inc Total Revenue for the quarter ending December 12, 2018 was $498m a 44.69% increase of 222m year over year
View Chart On Koyfin

Quarterly AMRX Long-Term Debt Data

12/2018$2,670m
09/2018$2,675m
06/2018$2,681m
03/2018$1,392m
12/2017$1,395m
09/2017$1,398m
12/2016$1,160m

Annual AMRX Long-Term Debt Data

2018$2,670m
2017$1,395m
2016$1,160m
2015$952m